Cancer accounts for about 23% of all deaths, ranking second to heart diseases. There is a strong need for targeted cancer therapies acting alone or as components of combinatorial treatments (e.g. synergy with radiotherapy or chemotherapy).

VAR2 Pharmaceuticals aims to develop treatments targeting major high-risk cancer forms and niche oncology indications. Our malaria protein's unique affinity and specificity for distinct cancer-associated carbohydrates can inhibit tumor growth, progression, migration and invasion capacity. These distinct cancer associated carbohydrates are attractive targets because of a central role in cell growth and cellular events leading to metastasis formation.

Our therapeutic strategy is focusing on using recombinant VAR2CSA to deliver a toxic payload as well as in immunotherapy approaches including bispecific and CAR-T strategies.